DISAIA et al., 1973 - Google Patents
Antibody cytotoxicity studies in ovarian and cervical malignanciesDISAIA et al., 1973
- Document ID
- 16077078427221878992
- Author
- DISAIA P
- NALICK R
- TOWNSEND D
- Publication year
- Publication venue
- Obstetrics & Gynecology
External Links
Snippet
This study evaluates the cytotoxic affect of serum from patients with progressive squamous cell carcinoma of the cervix and adenocarcinoma of the ovary prior to treatment. The cytotoxic ability of six specific rabbit antisera prepared by immunizing rabbits with fresh …
- 108090001123 antibodies 0 title abstract description 5
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/828—Cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Greaves et al. | Antisera to acute lymphoblastic leukemia cells | |
| Vadhan-Raj et al. | Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. | |
| Baldwin et al. | Detection of circulating hepatoma D23 antigen and immune complexes in tumour bearer serum | |
| McCoy et al. | Inhibition of leukocyte migration by tumor-associated antigens in soluble extracts of human malignant melanoma | |
| Apuzzo et al. | Immunological aspects of intrinsic glial tumors | |
| Vaage | Specific desensitization of resistance against a syngeneic methylcholanthrene-induced sarcoma in C3Hf mice | |
| Morton et al. | Immune factors in human cancer: malignant melanomas, skeletal and soft tissue sarcomas | |
| Borowitz et al. | Lymphoblastic lymphoma with the phenotype of common acute lymphoblastic leukemia | |
| Holland et al. | Haemagglutinating, precipitating and lymphocyte-stimulating factors of phytohaemagglutinin | |
| US5882654A (en) | Polyvalent melanoma vaccine | |
| DISAIA et al. | Antibody cytotoxicity studies in ovarian and cervical malignancies | |
| LeBien et al. | Characterization of a xenoantiserum produced against three molar KCl-solubilized antigens obtained from a non-T, non-B (pre-B) acute lymphoblastic leukemia cell line | |
| Sokal et al. | Use of Bacillus Calmette-Guérin as adjuvant in human cell vaccines | |
| Hršak et al. | Mode of immunosuppressive action of Ehrlich ascitic fluid | |
| AU593229B2 (en) | Onco-fetal specific monoclonal antibodies methods of preparation and use | |
| US5840317A (en) | Composition comprising tumor cell lines containing GD2 ganglioside GM2 ganglioside, M-TAA, and either M-urinary antigen or M-fetal antigen | |
| Byfield et al. | Murine neuroblastoma cured in vivo by an antibody-dependent cellular cytotoxicity reaction | |
| HELLSTRÖM et al. | The role of cell-mediated immunity in control and growth of tumors | |
| Bystryn | Immunology and immunotherapy of human malignant melanoma | |
| Lanier et al. | Antigen-induced murine B-cell lymphomas. III. Passive anti-idiotype serum therapy and its combined effect with chemotherapy | |
| Mori et al. | Expression of heterophil Forssman antigen on cultured malignant cell lines | |
| Pass et al. | Antigens of human wart tissue. | |
| Pilch et al. | Lymphocyte-mediated immune responses in neoplasia | |
| DiSaia | Tumor-associated antigens in gynecologic cancer | |
| Ashley et al. | In vivo H‐2K and H‐2D antigen expression in two allogeneic mouse tumours of low immunogenicity |